PAT Data Will Not Be Evaluated During Drug Inspections – FDA
This article was originally published in The Tan Sheet
Executive Summary
As a general policy, FDA will not look at process analytical technology research data during drug inspections, FDA New Jersey District Director Douglas Ellsworth asserted during a recent industry-sponsored conference
You may also be interested in...
PAT Selective Implementation Advised As Cost Control Measure
The cost to pharmaceutical manufacturers of operating process analytical technology often is more than the cost of implementing it, according to Pfizer Drug Product Technology Senior Manager Joep Timmermans
FDA Will Propose Drug GMP Quality Management Systems By December
FDA expects to release a draft on improving the agency's drug GMP management systems by Dec. 1
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC